Press Releases May 13, 2026 04:30 PM

EDAP | Focal One to Host Investor Day on June 1, 2026

EDAP TMS SA announces Investor Day on June 1, showcasing growth strategy and innovation in focal therapy technology

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
EDAP

EDAP TMS SA, a Nasdaq-listed leader in robotic energy-based therapies, will hold an Investor Day on June 1, 2026, to present its business plans, long-term financial targets, and innovations in focal therapy technology, including expanding therapeutic indications. The event aims to engage analysts and investors with insights from the executive leadership team and medical experts.

EDAP | Focal One to Host Investor Day on June 1, 2026
EDAP
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Investor Day scheduled for June 1, 2026, to discuss growth strategy and financial goals.
  • Focus on expanding therapeutic indications for the Focal One HIFU platform beyond prostate cancer.
  • Emphasis on leadership in focal therapy through innovation in imaging, robotics, and non-invasive energy delivery technologies.

, May 13, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Host Investor Day on June 1, 2026

AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at 8:00 am ET on Monday, June 1, 2026.

The presentation will be led by members of the Company’s Executive Leadership Team and will include remarks from a prominent urologic surgeon and expert in focal therapy and Focal One HIFU. The event will also cover an overview of the Company’s business plans and strategic path forward, including our:

  • Growth Strategy and Long-Term Financial Targets
  • Expanding Therapeutic Indications to Increase Clinical Opportunity
  • Focal Therapy Leadership through Innovation and Advanced Technologies

The Company invites participants to join the event via the registration link below and on the Events and Presentations section of the Focal One Investor Relations website. A replay of the webcast and associated slide presentation will be available on the company’s website.

For inquiries about this event, please contact investor.relations@focalone.com or louisa@gilmartinir.com.

Investor Day Details:

Date:                Monday, June 1st

Time:                8:00-10:00 am ET

Registration:      https://edge.media-server.com/mmc/p/x7gnq8wb

About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes, and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics, and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and the United States as a leading prostate focal therapy controlled by urologists, with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.

Investor Contacts
Investor Relations
EDAP TMS SA
investor.relations@focalone.com


Risks

  • Dependence on successful expansion of therapeutic indications which may face regulatory or clinical challenges.
  • Market adoption risk of new medical technologies and competition within the medical device sector.
  • Potential uncertainties in achieving long-term financial targets amid evolving healthcare regulations and market dynamics.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026